Humanwell Healthcare (Group) Co.,Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Humanwell Pharmaceutical Group Co., Ltd. (600079. SH) was established in 1993 and listed on the Shanghai Stock Exchange in 1997. It is a leading enterprise in the pharmaceutical industry in Hubei Province, one of the top 30 pharmaceutical companies in China, a national technology innovation demonstration enterprise, and a leading enterprise in the internationalization of pharmaceutical preparations in China. It has formed a leadership or leading position in sub fields such as nervous system medication, steroid hormone drugs, and Uyghur ethnic medicine, and has gradually expanded its generic drug business in the United States in recent years. The company focuses on the pharmaceutical industry, supplemented by pharmaceutical commerce, and steadily promotes internationalization. The pharmaceutical industry has achieved full dosage form production capacity across the entire industry chain of pharmaceutical intermediates, raw materials, pharmaceutical excipients, and pharmaceutical formulations; The pharmaceutical business adheres to the positioning of "comprehensive medical service supplier", layout the commercial network, and achieve full regional coverage; Internationalization has formed a global pharmaceutical full value chain capability for research and development, registration, production, and sales, with over 80 products exported to over 70 countries and regions worldwide. The company is based on high-end generic drugs, innovative formulations, and innovative drugs with high clinical value, targeting cutting-edge fields and creating a first-class innovative research and development industrialization platform. The group has over 200 products under research, over 20 Class 1 new drugs under research, and 24 projects have been listed as national major new drug innovation projects, with 621 authorized patents. Humanwell Pharmaceutical firmly adheres to the development strategy of "becoming a leader in the pharmaceutical segmented market", and through the three strategic paths of "focus, innovation, and internationalization", aims to create a globally competitive first-class pharmaceutical enterprise in China. |
| Headquarter | Wuhan |
| Establish Date | 3/30/1993 |
| Listed Code | 600079.SH |
| Listed Date | 6/6/1997 |
| Chairman | Li Jie. |
| CEO | Deng Xiafei. |
| Website | www.humanwell.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
